B2iDigital
Oct 29, 6:31 PM
Asked why infected diabetic foot ulcers so often progress beyond the mild stage, Charles Zelen, DPM, FACFAS, founder and president of PERI, the clinical research organization conducting the company's Phase 2a trial of Nu-3, told a Lakewood-Amedex Biotherapeutics Inc. (Nasdaq:
$LABT ) virtual roundtable that these patients are compromised hosts with multiple complex comorbidities and poor circulation.
Lakewood-Amedex Biotherapeutics Inc. is a B2i Digital Featured Company. See the company's in-depth profile at: https://b2idigital.com/lakewood-amedex-biotherapeutics-inc-1
Zelen set out factors that, as he put it, have to be addressed simultaneously to heal these wounds:
• Patients with poor circulation tend to have even greater problems dealing with infection and with bad wounds, he said
• Neuropathy leaves patients unable to feel the infection going on, so it is often caught later, which he said makes it more difficult to treat
• The wounds carry chronic inflammation and a complex wound environment, in his description, and antimicrobial resistance is also a big factor in this patient population
Zelen closed by calling diabetic foot ulcers a serious and growing medical challenge, despite all the advances in wound care. "So this is a very big problem, very complicated problem, and one that we very much need to solve," Zelen noted, "or we're going to end up with a lot of lost extremities and a lot of deaths."
Watch the full roundtable: https://youtu.be/EOIfDh8Vykk
Lakewood-Amedex Biotherapeutics Inc. (Nasdaq: LABT) is a clinical-stage biotechnology Company developing a novel class of fast-acting, broad-spectrum antimicrobials, the Bisphosphocin® class, to treat infectious diseases and reduce the threat posed by antibiotic-resistant bacterial strains, including MRSA, VRE, and others. For more information, please visit https://lakewoodamedex.com.
Discover more Featured Companies, Featured Experts, and upcoming Featured Conferences at b2idigital.com.
David Shapiro, Chief Executive Officer of B2i Digital, personally purchased in the open market and currently owns shares of unrestricted LABT stock, in line with B2i Digital’s practice of investing alongside its Featured Companies. B2i Digital is not a broker-dealer or investment adviser. This post is informational and not an offer or solicitation regarding any security. See the complete Disclosure at https://b2idigital.com/disclaimer.
$SPRO,
$CDTX,
$SCYX,
$XBI
1 replies